Article citationsMore >>

Salmenniemi, U. and K. Remes, Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep, 2012. 4(2): p. e13.

has been cited by the following article:

Article

Late Presentation of Carfilzomib Associated Thrombotic Microangiopathy

1Department of internal Medicine, State University of New York-Downstate, Brooklyn, New York, USA

2Saint James School of Medicine St. Vincent, Cane Hall Road, Arnos Vale, St Vincent & the Grenadines

3Department of Hematology & Oncology, State University of New York-Downstate, Brooklyn, New York, USA


American Journal of Medical Case Reports. 2019, Vol. 7 No. 10, 240-243
DOI: 10.12691/ajmcr-7-10-5
Copyright © 2019 Science and Education Publishing

Cite this paper:
Michael Haddadin, Mohammad Al-Sadawi, Sally Madanat, Eric Tam, Evelyn Taiwo, Carol Luhrs, Samy I Mcfarlane. Late Presentation of Carfilzomib Associated Thrombotic Microangiopathy. American Journal of Medical Case Reports. 2019; 7(10):240-243. doi: 10.12691/ajmcr-7-10-5.

Correspondence to: Samy  I Mcfarlane, Department of internal Medicine, State University of New York-Downstate, Brooklyn, New York, USA. Email: Samy.mcfarlane@downstate.edu

Abstract

Multiple Myeloma (MM) is a plasma cell disorder characterized by abnormal proliferation of plasma cells resulting in overproduction of paraprotein. Proteasome inhibitors (PI) have been a corner stone for the treatment of MM. Thrombotic Microangiopathy (TMA) is a recent hematological adverse event that has newly been recognized in multiple PI. TMA leads to end-organ damage and infarction by microthromobi. TMA pathophysiology is not well understood and has multiple etiologies. We present a case of PI-induced TMA, along with literature review of cases diagnosed from 2008-2018. Unique to our case is the onset of presentation, more than 24 months after initiating carfilzomib. Our case highlights the need for vigilant monitoring and the importance of clinical suspicion in patients at risk for TMA.

Keywords